P&F Products & Features GmbH annonce l'acquisition d'AVVie GmbH

P&F Products & Features GmbH has announced the acquisition of AVVie GmbH, a strategic move aimed at enhancing its portfolio in the structural heart disease sector. The deal, finalized on August 5, 2026, involves an undisclosed amount and is expected to significantly bolster P&F's capabilities in developing innovative treatments for mitral valve regurgitation, a condition affecting millions globally.

AVVie GmbH, founded by cardiac surgeon Professor Werner Mohl, has developed the AngelValve™ augmentation system, an innovative transcatheter solution addressing unmet needs in the treatment of mitral valve pathologies. The AngelValve™ platform is designed for patients who have limited or no therapeutic options, targeting a significant medical gap. Currently, over 13 million individuals in Europe and the United States suffer from mitral regurgitation, yet only a small fraction—approximately 5%—receive appropriate treatment for moderate to severe cases. This acquisition aligns with P&F's mission to improve patient quality of life by addressing this therapeutic deficit.

The integration of AVVie’s research and development infrastructure and intellectual property with P&F’s global expertise in product development, clinical affairs, regulatory processes, manufacturing, and commercialization positions the combined entity to accelerate innovation and shorten development timelines. The leadership at P&F, including CEO Dr. Katharina Kiss, emphasizes the commitment to advancing treatments for structural heart diseases and enhancing the AngelValve™ platform. This partnership is expected to leverage exceptional engineering talent and proven development capabilities to transform AVVie’s innovation into effective treatments.

The acquisition reflects broader trends in the medical technology sector, where companies are increasingly seeking to consolidate resources and expertise to address complex health challenges. As the demand for effective treatments for structural heart diseases grows, driven by an aging population and rising prevalence of cardiovascular conditions, strategic acquisitions like this one are likely to become more common. P&F's commitment to innovation and its expanded portfolio position it favorably in a competitive market, potentially setting the stage for future growth and leadership in the cardiovascular treatment space.